GlassScriptPhysician profile
Lakshmi Gowda Hanumaiah
NPI 1770714370
$427.99
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.73 · 2020: $25.61 · 2021: $12.01 · 2022: $11.71 · 2023: $70.18 · 2024: $90.36 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $302.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.00 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $65.80 | 2019-2025 | Zepbound, Mounjaro |
| Xeris Pharmaceuticals, INC. | $45.12 | 2023-2025 | Gvoke Hypopen |
| Pfizer INC. | $38.26 | 2020-2022 | |
| Organon LLC | $34.01 | 2024-2025 | Nuvaring, Nexplanon |
| Exact Sciences Corporation | $26.40 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $22.70 | 2025 | Spravato |
| Verona Pharma, INC. | $18.87 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $17.80 | 2025 | Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $16.67 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $14.94 | 2025 | Airsupra |
| Neurocrine Biosciences, INC. | $13.48 | 2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Gowda Hanumaiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.